Eisai Expects Leqembi® Revenue to Reach JPY 143.5 Billion in Fiscal 2026

Eisai Co., Ltd., in a recent announcement, has projected that their Alzheimer's treatment, Leqembi® (lecanemab), will generate revenues totaling approximately JPY 143.5 billion (or around SEK 8.4 billion) for the fiscal year 2026, spanning from April 2026 to March 2027. This represents a remarkable growth of 63% compared to the previous year, highlighting the increasing demand for innovative treatments in the realm of neurodegenerative diseases.

A Collaborative Effort

Leqembi, a groundbreaking therapy for early Alzheimer's disease, is the product of a longstanding collaboration between Eisai and BioArctic AB. The unique antibody was initially developed based on the research of Professor Lars Lannfelt, who discovered the Arctic mutation associated with the disease. Eisai is accountable for the clinical development and commercialization aspects of Leqembi, while BioArctic holds the rights for its marketing in the Nordic region. Both companies are currently preparing for a joint effort to commercialize this promising treatment, which has already gained approval in 53 countries, with ongoing regulatory reviews in another six.

Impressively High Royalty Projections

Eisai's projections further indicate that the success of Leqembi will translate into approximately SEK 880 million in royalties for BioArctic during the same period. This financial forecast underscores the value of their partnership and the critical role that Leqembi plays in addressing the pressing issues surrounding Alzheimer's disease.

Wide Acceptance and Future Prospects

Leqembi is not just gaining traction in sales; it has also been recognized for its efficacy. After an initial treatment regimen involving dosing every two weeks for 18 months, a maintenance dosing schedule has been approved in several countries, including the United States, the United Kingdom, China, and Japan. Notably, in the U.S., Leqembi is approved for subcutaneous administration with an autoinjector, paving the way for more accessible and user-friendly options for patients.

Moreover, Eisai's efforts to introduce a subcutaneous version of Leqembi are in full swing, with applications underway in key markets across the globe, including Japan and China. This ongoing development signifies a robust pipeline of innovation aimed at maximizing the benefits of Leqembi and making it more widely accessible.

Continued Research and Development

As part of its commitment to advancing Alzheimer's research, Eisai is conducting pivotal clinical studies such as the AHEAD 3-45 trial, which focuses on patients with preclinical Alzheimer's disease. This extensive study, backed by public-private partnerships, aims to address the significant unmet needs within the Alzheimer’s community and to reinforce the efficacy of lecanemab as a treatment.

In alignment with these efforts, BioArctic is actively engaged in a variety of research projects targeting other neurodegenerative diseases such as Parkinson's disease and ALS. This broader research portfolio, enriched by proprietary technologies like BrainTransporter™, showcases BioArctic's commitment to groundbreaking advancements in neurology.

Conclusion

The outlook for Leqembi appears exceedingly positive, reflecting growing recognition of its potential to reshape the landscape of Alzheimer's disease treatment. With substantial revenue forecasts and a commitment to continued innovation, both Eisai and BioArctic stand at the forefront of a critical fight against neurodegenerative disorders. As they prepare for the future and expand into new markets, we remain hopeful for the positive impact that Leqembi and its successors will have on countless lives worldwide.